Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAgomAb Therapeutics NV Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | $1.04 | $1.29 | $1.18 |
| Q2 2026 | 2 | -$1.05 | -$0.92 | -$0.97 |
| Q3 2026 | 2 | -$1.25 | -$0.93 | -$1.11 |
| Q4 2026 | 3 | -$1.32 | -$1.00 | -$1.19 |
| Q1 2027 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q2 2027 | 1 | -$0.50 | -$0.50 | -$0.50 |
| Q3 2027 | 1 | -$0.51 | -$0.51 | -$0.51 |
| Q4 2027 | 1 | -$0.52 | -$0.52 | -$0.52 |
AgomAb Therapeutics NV Earnings Date And Information
AgomAb Therapeutics NV last posted its earnings results on Thursday, August 6th, 2026. The company reported $-0.91365 earnings per share for the quarter, missing analysts' consensus estimates of $1.18 by $2.09365. The company had revenue of 0 for the quarter and had revenue of 0 for the year. AgomAb Therapeutics NV has generated $-1 earnings per share over the last year ($-1.28 diluted earnings per share) and currently has a price-to-earnings ratio of -12.91. AgomAb Therapeutics NV has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
AgomAb Therapeutics NV Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 12/31/2025 | Q4 2025 | N/A | -$0.36 | N/A | $0 | $0 |
| 09/30/2025 | Q3 2025 | N/A | -$0.43 | N/A | N/A | $0 |
| 04/27/2026 | Q4 2024 | N/A | -$0.32 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
AgomAb Therapeutics NV Earnings: FAQ's
The conference call for AgomAb Therapeutics NV's latest earnings report can be listened to online.
The conference call transcript for AgomAb Therapeutics NV's latest earnings report can be read online.
AgomAb Therapeutics NV (:AGMB) has a recorded net income of $-62,547,000.AgomAb Therapeutics NV has generated $-1.28 earnings per share over the last four quarters.
AgomAb Therapeutics NV (:AGMB) has a price-to-earnings ratio of -12.91 and price/earnings-to-growth ratio is -0.13.